Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

被引:4
|
作者
Boiko, Anastasiia S. [1 ]
Mednova, Irina A. [1 ]
Kornetova, Elena G. [1 ,2 ]
Goncharova, Anastasiia A. [1 ]
Semke, Arkadiy, V [1 ]
Bokhan, Nikolay A. [1 ,2 ]
Ivanova, Svetlana A. [1 ,2 ]
机构
[1] Russian Acad Sci, Mental Hlth Res Inst, Tomsk Natl Res Med Ctr, Aleutskaya Str 4, Tomsk 634014, Russia
[2] Siberian State Med Univ, Dept Psychiat Addictol & Psychotherapy, Moskovsky Tract 2, Tomsk 634050, Russia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2022年 / 12卷 / 10期
基金
俄罗斯科学基金会;
关键词
schizophrenia; metabolic syndrome; antipsychotics; body mass index; insulin; leptin; ghrelin; LEPTIN; GHRELIN; COMPONENTS; RESISTANCE; OLANZAPINE; PEOPLE; ADULTS; MASS;
D O I
10.3390/jpm12101655
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Metabolic syndrome (MetS) is a common complication of schizophrenia that is quite exacerbated by long-term use of (atypical) antipsychotics. The mechanism of MetS has neuronal, neuroendocrine, and neuroimmunological components and shows some overlap with those of aspects of schizophrenia. We examined 195 patients with schizophrenia (90 with and 105 without MetS) for the association of serum levels of ghrelin, insulin, and leptin with metabolic abnormalities. Serum glucose levels and lipid profiles were routinely measured with colorimetric enzymatic methods and hormone levels with multiplex analyzers. Leptin levels were highly significantly increased (p < 0.001) in people with MetS (9.966 [5.882; 21.496] vs. 6.35 [2.005; 11.753], Me [Q1; Q3]) and ghrelin levels were actually significantly decreased (p = 0.045). Insulin levels did not differ significantly between those with and without MetS (p = 0.162). In Spearman's correlation analysis between the hormone levels, body characteristics, and biochemical parameters, significant correlations were seen somewhat more often in people without MetS than in those with MetS and also less often for ghrelin than for the other hormones. We conclude that evidence exists for a role in the development of MetS especially for leptin, but that less is supporting a role for ghrelin.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome
    Boiko, A. S.
    Kornetova, E. G.
    Mednova, I. A.
    Loonen, A. J. M.
    Ivanova, S. A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S276 - S277
  • [2] Antipsychotic-Induced Metabolic Syndrome: A Review
    Akinola, Pelumi Samuel
    Tardif, Isabelle
    Leclerc, Jacinthe
    METABOLIC SYNDROME AND RELATED DISORDERS, 2023, 21 (06) : 294 - 305
  • [3] Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia
    Kuzman, Martina Rojnic
    Mueller, Daniel J.
    PHARMACOGENOMICS, 2012, 13 (08) : 843 - 846
  • [4] Antipsychotic-induced metabolic syndrome-A review
    Akinola, Pelumi Samuel
    Tardif, Isabelle
    Leclerc, Jacinthe
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 347 - 347
  • [5] The 'boon and bane' of antipsychotic-induced metabolic syndrome
    Venkatasubramanian, G.
    ACTA PSYCHIATRICA SCANDINAVICA, 2009, 120 (06) : 500 - 501
  • [6] Berberine for antipsychotic-induced metabolic syndrome in patients with schizophrenia spectrum disorders: abridged secondary publication
    Chan, M. Y.
    Man, S. C.
    Lam, M.
    Lai, W. H.
    Qin, Z. S.
    Ng, M. K. R.
    Lee, C. K.
    Chen, Y. H. E.
    Lee, H. M. E.
    Liu, L. Y.
    Wong, H. K.
    Zhang, Z. J.
    HONG KONG MEDICAL JOURNAL, 2023, 29 (03) : 4 - 7
  • [7] Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome
    Khasanova, Aiperi K.
    Dobrodeeva, Vera S.
    Shnayder, Natalia A.
    Petrova, Marina M.
    Pronina, Elena A.
    Bochanova, Elena N.
    Lareva, Natalia, V
    Garganeeva, Natalia P.
    Smirnova, Daria A.
    Nasyrova, Regina F.
    METABOLITES, 2022, 12 (08)
  • [8] Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia
    Scaini, Giselli
    Quevedo, Joao
    Velligan, Dawn
    Roberts, David L.
    Raventos, Henriette
    Walss-Bass, Consuelo
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (03) : 369 - 380
  • [9] POLYGENIC RISK FOR BODY MASS INDEX AND ANTIPSYCHOTIC-INDUCED METABOLIC SIDE EFFECTS INTERACT ON SEVERITY OF METABOLIC SYNDROME PHENOTYPES IN PATIENTS WITH SCHIZOPHRENIA
    De Mastro, Laura
    Kikidis, Gianluca C.
    Falcone, Rosa Maria
    Chen, Qiang
    Bigos, Kristin
    Pergola, Giulio
    Rampino, Antonio
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2022, 63 : E306 - E307
  • [10] Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia
    Casey, DE
    Haupt, DW
    Newcomer, JW
    Henderson, DC
    Sernyak, MJ
    Davidson, M
    Lindenmayer, JP
    Manoukian, SV
    Banerji, MA
    Lebovitz, HE
    Hennekens, CH
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 : 4 - 18